TrialESMO open2022

Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life.

E Van Cutsem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.